CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for McKesson Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

McKesson Corp
6555 State Highway 161
Phone: (972) 446-4800p:972 446-4800 IRVING, TX  75039  United States Ticker: MCKMCK
Business Summary
McKesson Corporation is a provider of diversified healthcare services. The Company is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023YesYes-YesYes

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
5047 Medical, dental, and hospital equipment and supplies
7372 Prepackaged software
7371 Computer programming services
7375 Information retrieval services
7373 Computer integrated systems design
5999 Miscellaneous retail stores, not elsewhere classified
8742 Management consulting services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Donald R.Knauss 73 4/1/2022 10/20/2014
Chief Executive Officer, Director Brian S.Tyler 56 3/1/2019 8/23/2012
Chief Financial Officer, Executive Vice President Britt J.Vitalone 1/1/2018 1/1/2018
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
McKesson Europe AG (ADR) Stockholmer Platz 1 STUTTGART Germany
Vantage Oncology Finance Co. 1500 Rosecrans Ave., Suite 400 Manhattan Beach CA United States
Vantage Oncology Holdings LLC 1500 Rosecrans Avenue Manhattan Beach CA United States
21 additional Subsidiary records available in full report.

Business Names
Business Name
Attentus Medical Sales, Inc.
Biologics, Inc.
Canada Distribution Holdings Limited Partnership
32 additional Business Names available in full report.

General Information
Number of Employees: 45,000 (As of 3/31/2023)
Outstanding Shares: 131,408,286 (As of 12/31/2023)
Shareholders: 4,425
Stock Exchange: NYSE
Federal Tax Id: 943207296
Fax Number: (302) 636-5454
Email Address: investors@mckesson.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024